On June 29, 2026, CorMedix Inc. restructured its executive leadership. Elizabeth Hurlburt, previously the Chief Operating Officer, was appointed to the new role of Chief Operating and Commercial Officer, gaining oversight of commercial functions, medical affairs, regulatory, and clinical operations. Concurrently, Michael Seckler departed the company. CorMedix is a biopharmaceutical company that develops and commercializes therapeutic products.
